Literature DB >> 32086878

Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.

Geoffroy Liegeon1, Guillemette Antoni2, Gilles Pialoux3, Catherine Capitant2, Laurent Cotte4, Isabelle Charreau2, Cécile Tremblay5, Eric Cua6, Eric Senneville7, François Raffi8,9, Laurence Meyer2,10, Jean-Michel Molina1,11,12.   

Abstract

INTRODUCTION: Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is associated with a small but statistically significant decrease in estimated glomerular filtration rate (eGFR). We assessed the renal safety of on-demand PrEP with TDF/FTC in HIV-1 uninfected men.
METHODS: We used data from the randomized double-blind placebo-controlled ANRS-IPERGAY trial and its open-label extension conducted between February 2012 and June 2016 among HIV-uninfected MSM starting on-demand PrEP. Using linear mixed model, we evaluated the mean eGFR decline from baseline over time and determined risks factors associated with eGFR decline during the study.
RESULTS: During the blind phase, with a median follow-up of 9.4 months, the mean decline slope of eGFR from baseline was -0.88 and -1.53 mL/min/1.73 m2 per year in the placebo (n = 201) and the TDF/FTC group (n = 198) respectively, with a slope difference of 0.65 mL/min/1.73 m2 per year (p = 0.27). Including both phases, 389 participants started on-demand TDF/FTC with a median follow-up of 19.2 months and a mean decline of eGFR from baseline of -1.14 mL/min/1.73 m2 per year (p < 0.001). The slope of eGFR reduction was not significantly different in participants with baseline eGFR ≤ 90 mL/min/1.73 m2 (p = 0.44), age >40 years (p = 0.24) or hypertension (p = 0.21). There was a dose-response relationship between recent tenofovir exposure and lower eGFR when considering the number of pills taken in the two months prior the visit (eGFR difference of -0.88 mL/min/1.73 m2 between >15 pills/month vs. ≤15 pills/month, p < 0.01) or plasma tenofovir concentrations at the visit (eGFR difference compared to ≤2 ng/mL: >2 to ≤10ng/mL: -0.98 mL/min/1.73 m2 , >10 to ≤40ng/mL: -1.28 mL/min/1.73 m2 , >40 ng/mL: -1.82 mL/min/1.73 m2 , p < 0.001). Three participants discontinued TDF/FTC for eGFR < 60 mL/min/1.73 m2 during the OLE phase. No case of Fanconi syndrome was reported.
CONCLUSIONS: The renal safety of on-demand PrEP with TDF/FTC was good. The overall reduction and intermittent exposure to TDF/FTC may explain this good renal safety.
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Entities:  

Keywords:  HIV; PrEP; eGFR; intermittent; kidney; on-demand; tenofovir

Year:  2020        PMID: 32086878      PMCID: PMC7035456          DOI: 10.1002/jia2.25420

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


  24 in total

1.  Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.

Authors:  Kenneth K Mugwanya; Christina Wyatt; Connie Celum; Deborah Donnell; James Kiarie; Allan Ronald; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

2.  Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.

Authors:  Julia L Marcus; Leo B Hurley; Charles Bradley Hare; Dong Phuong Nguyen; Tony Phengrasamy; Michael J Silverberg; Juliet E Stoltey; Jonathan E Volk
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-15       Impact factor: 3.731

3.  Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.

Authors:  Vasantha Jotwani; Rebecca Scherzer; David V Glidden; Megha Mehrotra; Patricia Defechereux; Albert Liu; Monica Gandhi; Michael Bennett; Steven G Coca; Chirag R Parikh; Robert M Grant; Michael G Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

4.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Authors:  Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

5.  Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Authors:  Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt
Journal:  J Infect Dis       Date:  2016-03-29       Impact factor: 5.226

6.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

7.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

8.  Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Authors:  Amanda Mocroft; Jens D Lundgren; Michael Ross; Christoph A Fux; Peter Reiss; Olivier Moranne; Philippe Morlat; Antonella d'Arminio Monforte; Ole Kirk; Lene Ryom
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP.

Authors:  Victoria Pilkington; Andrew Hill; Sophie Hughes; Nneka Nwokolo; Anton Pozniak
Journal:  J Virus Erad       Date:  2018-10-01
View more
  3 in total

Review 1.  Delayed presentation of HIV among older individuals: a growing problem.

Authors:  Amy C Justice; Matthew B Goetz; Cameron N Stewart; Brenna C Hogan; Elizabeth Humes; Paula M Luz; Jessica L Castilho; Denis Nash; Ellen Brazier; Beverly Musick; Constantin Yiannoutsos; Karen Malateste; Antoine Jaquet; Morna Cornell; Tinei Shamu; Reena Rajasuriar; Awachana Jiamsakul; Keri N Althoff
Journal:  Lancet HIV       Date:  2022-02-23       Impact factor: 16.070

2.  Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.

Authors:  Karla Cristina Silva Petruccelli; Djane Clarys Baía-da-Silva; Fernando Val; Monica Santos Valões; Nadia Cubas-Vega; Alexandre Vilhena Silva-Neto; Vanderson Sampaio; Aline Alencar; Roberto Pecoits-Filho; Rodrigo Carvalho Moreira; Sandra Wagner Cardoso; Ronaldo I Moreira; Iuri Costa Leite; José Valdez Madruga; Esper G Kallas; Paulo R Alencastro; Brenda Hoagland; Beatriz Grinsztejn; Valdiléa Gonçalves Veloso Santos; Marcus Vinícius Guimarães Lacerda
Journal:  AIDS Res Ther       Date:  2022-02-24       Impact factor: 2.250

3.  Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.

Authors:  Robin Schaefer; Pedro Henrique Amparo da Costa Leite; Ronaldo Silva; Quarraisha Abdool Karim; Christopher Akolo; Carlos F Cáceres; Inês Dourado; Kimberly Green; Anita Hettema; Elske Hoornenborg; Smarajit Jana; Bernhard Kerschberger; Hally Mahler; Sindy Matse; Hamish McManus; Jean-Michel Molina; Sushena Reza-Paul; Iskandar Azwa; Maryam Shahmanesh; Doug Taylor; Hamid Vega-Ramirez; Valdiléa G Veloso; Rachel Baggaley; Shona Dalal
Journal:  Lancet HIV       Date:  2022-03-07       Impact factor: 16.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.